UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 27, 2005
BIOPHAN TECHNOLOGIES, INC.
--------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 0-26057 82-0507874
----------------------------- ------------- -----------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
150 Lucius Gordon Drive, Suite 215
West Henrietta, New York 14586
--------------------------------------- ---------
(Address of principal executive offices) (Zip code)
(585) 214-2441
-------------------------
(Registrant's telephone number)
Item 7.01 Regulation FD Disclosure
At our Annual Stockholders Meeting on July 27, 2005, we announced a new
strategic initiative to enter the field of cardiovascular diagnostic and
therapeutic devices. Simultaneously, we issued a press release, dated July 27,
2005, announcing the initiative. The press release is filed herewith as Exhibit
99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
Number Exhibit
99.1 Press Release dated July 27, 2005: Biophan Launches Strategic
Initiative to Enter High-Growth Market for Cardiovascular Devices
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHAN TECHNOLOGIES, INC.
--------------------------
(Registrant)
Date 7/27/05 /s/ Robert J. Wood
---------------- -----------------------------
(Signature)
Robert J. Wood
CFO, Treasurer, Secretary
(Principal Financial Officer)
2